Lucio Gordan, MD, president and managing physician of Florida Cancer Specialists & Research Institute, discusses recently updated clinical guidelines from the National Comprehensive Cancer Network (NCCN) in multiple myeloma, which specifically discuss disease staging and risk stratification and advise clinicians on how to address 1q abnormalities.

Dr Lucio Gordan Discusses Updated Guidelines Addressing 1q Abnormalities in Multiple Myeloma

In this interview, Dr. Joseph Kalis, Ambulatory Oncology Clinical Pharmacy Specialist at the University of Colorado Health, speaks with i3 Health and the Pharmacy Podcast Network to share an exclusive preview of the recent CPE activity that he developed with i3 Health, Aligning Treatment Goals and Value-Based Care in Newly Diagnosed Multiple Myeloma. After the interview, stay tuned to hear the full presentation from Dr. Kalis and his co-chair, Dr. Eric Cannon, Chief Pharmacy Benefits Officer at SelectHealth, and claim free CPE credit for the activity at https://bit.ly/45WA5hR. 
-----
DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES
i3 Health and St. John Fisher University Wegmans School of Pharmacy (WSOP) endorse the standards of the ACPE that require everyone in a position to control the content of a CPE activity to disclose all financial relationships with ineligible companies that are related to the content of the CPE activity. CPE activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when an individual has an opportunity to affect CPE content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.

i3 Health and St. John Fisher University Wegmans School of Pharmacy (WSOP) will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health and St. John Fisher University Wegmans School of Pharmacy (WSOP) does not endorse any products or services.

Relevant financial relationships exist between the following individuals and ineligible companies:

The i3 Health planners, reviewers, and managers have nothing to disclose.

St. John Fisher University Wegmans School of Pharmacy (WSOP) staff members have no relevant financial relationships to disclose.

Eric Cannon, PharmD, FAMCP, has no relevant financial relationships to disclose.

Joseph A. Kalis, PharmD, BCOP, has no relevant financial relationships to disclose.

i3 Health has mitigated all relevant financial relationships.

Additional Advances in Newly Diagnosed Multiple Myeloma: Interview + Free CPE Podcast

For Multiple Myeloma Awareness Month this March, Oncology Data Advisor hosted a live panel discussion geared towards patients living with multiple myeloma. Dr. Rahul Banerjee, Dr. Alankrita Taneja, Dr. Richa Thakur, and Dr. Gurbakhash Kaur helped put the myriad of new developments in multiple myeloma treatment into perspective for patients and answered questions from the audience regarding current and future treatment strategies for multiple myeloma.

Multiple Myeloma Awareness Month 2024: What Patients Need to Know

Yelak Biru, President and CEO of the International Myeloma Foundation (IMF), joins the show to share his remarkable personal and professional journey. After immigrating to the US from Ethiopia, Yelak was diagnosed with multiple myeloma at the age of 26, setting him on an extraordinary path as both a survivor and a passionate advocate for myeloma patients. He discusses pivotal moments in his treatment, including seeking second opinions, utilizing groundbreaking therapies like CAR-T, and his ongoing decision to reject a transplant. Now leading the world’s first and largest nonprofit dedicated to improving the lives of those impacted by multiple myeloma, Yelak shares his vision for expanding IMF's global outreach, advancing research, and empowering patients and caregivers worldwide.

Learn more about the IMF.
https://www.myeloma.org/

Check out Chadi’s website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/

Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

Survivorship and the International Myeloma Foundation With Yelak Biru

Dr. Joe Mikhael, Chief Medical Officer of the International Myeloma Foundation (IMF) and Professor at TGen, takes us beyond his medical career to explore the personal experiences that have shaped his journey in oncology. Dr. Mikhael discusses the IMF’s targeted strategies for reducing health disparities among diverse ethnic and racial groups affected by myeloma, shedding light on specific initiatives aimed at improving access and outcomes. He also dives into his role in medical education, where he mentors the next generation of oncologists through innovative fellowship programs, advancing research, and fostering a more inclusive approach to cancer care.

Check out Chadi’s website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/

Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

Fireside Chat With CMO of IMF Joe Mikhael

Emma and Summer meet with oncology analysts Neha Anand and David Dahan, to discuss an emerging class of drugs: bispecific antibodies.

November 2024 Datamonitor Healthcare Podcast: Bispecific Antibodies in Oncology

Returning to the show, Drs. Vincent Rajkumar and Aaron Goodman engage in a dynamic debate over the evolving landscape of smoldering multiple myeloma, focusing on the highly anticipated study recently co-authored by Dr. Rajkumar and published in The New England Journal of Medicine after being presented at ASH 2024. They dissect the study’s findings, which highlight the impact of early intervention with daratumumab in delaying disease progression for patients classified as high-risk. The discussion explores the nuances of smoldering myeloma classification, the controversy surrounding risk stratification, and the historical context of prior studies that failed to change clinical practice. With their expert insights, Drs. Rajkumar and Goodman break down the implications of this research, questioning whether it truly shifts the standard of care and what it means for future treatment approaches.

View the NEJM publication.
https://www.nejm.org/doi/abs/10.1056/NEJMoa2409029

Check out Chadi’s website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/

Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

Smoldering Myeloma: The Epic Debate

Cancer survivor, Michelle, was 48 when she first heard the words “multiple myeloma”. It wasn’t a diagnosis she expected—her doctor didn’t even think it was a possibility.

The incurable blood cancer is the second most common of its kind and demands lifelong treatment, which often comes with devastating physical, mental and emotional costs. 
Now, a new research survey is giving people with myeloma, smouldering myeloma (SMM), and monoclonal gammopathy of undetermined significance (MGUS) the chance to share their experiences, with the goal of shaping better support and care in the future.

Michelle and project leader, Dr Natalie Tuckey joined Caroline Winter on ABC Evenings to discuss.

Myeloma and mental health

On this episode, Mary Caffrey, Executive Editor of AJMC and Evidence-Based Oncology (EBO), is joined by Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO Chief Medical Officer of the International Myeloma Foundation (IMF), was the primary interviewee and source for a recent EBO article. His insights in that piece highlight how the IMF’s M-Power initiative builds trust and awareness through its 3-pillar approach: community engagement, primary care education, and improving care for patients. During the discussion, Mikael talks about how IMF's M-Power initiative is expanding with the organization's medical student scholars program, using patient narratives to encourage trial participation among Black patients, and navigating today’s political climate around diversity, equity, and inclusion—all while pushing toward a future where lifesaving treatments and cures reach every patient who needs them. Stay tuned for this enlightening discussion on bridging the clinical trial gap.

Hope on the Horizon for Underserved Patients With Multiple Myeloma: Joseph Mikael, MD

A Day in the Life of Mindy Fast & Mike Kastner | Navigating the Multiple Myeloma Journey

Citeline places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge and insight, by providing the perfect combination of news and information together with penetrating insight and analysis. Citeline is a leader in the field of healthcare industry information.

The mission of Oncology Data Advisor is to provide the multidisciplinary team with expert insights into clinical best practices and research progress in cancer care.

The International Myeloma Foundation (IMF) is the world’s first and largest myeloma organization, reaching more than 525,000 members in 140 countries.

Founded in 1990, the IMF is a non-profit organization dedicated to improving the quality of life of myeloma patients and their families.

The IMF funds research, provides education, lends
support, and promotes advocacy initiatives that allow collective voices to be heard.

The IMF’s dedicated and diverse staff provides immediate help. Our knowledgeable and compassionate professionals can be reached via email at TheIMF@myeloma.org or our toll-free InfoLine 800-452-CURE (2873).

Healthcare Unfiltered is an honest, raw, timely podcast tackling any and all topics in healthcare that affect stakeholders. Dr. Chadi Nabhan uses his dynamic conversational skills to challenge his guests to address controversial and important topics. He also brings on world renowned experts to discuss clinical advances in medicine.

New tracks tagged #multiple myeloma